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Introduction
Clinical Guideline CG3 from the National Institute for Health and Clinical Excellence (NICE) makes recommendations on appropriate clinical practice in preoperative testing for elective surgery. 1 The guidelines include laboratory testing and clinical biochemists may have an interest in them as representing best use of laboratory resources. This article reviews the evidence on which the guidance on laboratory testing is based and potential problems with implementation of the recommendations.
Background to the guidance Evidence used to create the guidelines NICE Clinical Guidelines are based on best evidence gathered from a systematic evaluation of published papers. After rejection of 'ineligible'studies, evidence was available to the NICE working group from 29 papers for full blood count (FBC) and haemoglobin, 29 papers on haemostasis tests, no papers on sickle cell testing, nine papers on 'biochemistry test', 15 papers on 'urine test', seven papers on pregnancy tests and four papers on 'blood gases test'. The data available to NICE are summarized below.
FBC and haemoglobin
Abnormal results were shown to be present in 0.4--32.2% of patients, with a change in management resulting in 0--6.5% and post-operative complications in 0--1.1% abnormal results. However, inclusion criteria in the studies were all signi¢cantly di¡erent and no papers evaluated the health outcomes in patients tested compared with those not tested. Furthermore, there was no age strati¢cation in the data. Consequently, the evidence available was insu⁄cient to determine whether these tests did or did not a¡ect patient outcome.
Haemostasis tests
Abnormal results were shown to be present in 0.4--45.9% of patients, with a change in management resulting in 0--7.3% and post-operative complications in 0--8.1% abnormal results. However, inclusion criteria in the studies were all signi¢cantly di¡erent, and only four papers gave information about the American Society of Anesthesiologists (ASA) grade of anaesthetic risk. The de¢nition of changes in management varied from blood transfusion to broader, more variable measures. No papers evaluated the health outcomes in patients tested compared with those not tested. Furthermore, there was little age strati¢cation in the data and only one paper suggested that preoperative results were correlated with adverse outcomes. Consequently, the evidence available was insu⁄cient to determine whether these tests did or did not a¡ect patient outcome.
Biochemistry tests
Abnormal results were shown to be present in 0.4--81.3% of results for electrolyte assay, leading to change in management in 0--10.5% of cases; 0.2--27.0% of urea/creatinine samples, leading to change of management in 0--5.5% of cases; and 0.4--71.5% of glucose samples, leading to change of management in 0--2.1% of cases. Insu⁄cient detail was provided to allow evaluation of test utility by ASA grade or patient age. No papers evaluated the health outcomes in patients tested compared with those not tested. Consequently, the evidence available was insuf-¢cient to determine whether these tests did or did not a¡ect patient outcome.
Urine tests
Abnormal results were shown to be present in 0.8--34.1% of patients, with a change in management resulting in 0--14.3% (cancellation/delay of surgery [7 studies] or changes to treatment plan [4 studies]) and post-operative complications in 0--0.6%. However, inclusion criteria in the studies were all signi¢cantly di¡erent and some only included adults over 60 years of age. Three papers did include ASA grade, and there was a tendency for more abnormal results to be found in patients with higher grades of surgery. No papers evaluated the health outcomes in patients tested compared with those not tested. Furthermore, there was no age strati¢cation in the data. Consequently, the evidence available was insu⁄cient to determine whether these tests did or did not a¡ect patient outcome.
Pregnancy test
Positive tests were found in 0--2.2% of women and in all but one study a positive result always caused a change in management (cancellation/postponement due to the risk to the fetus). In the study where this did not happen, one woman had an emergency operation with no change in anaesthetic technique and su¡ered a miscarriage post-surgery. The variation in test positivity rate was shown to be related to the age range in the study, with the lowest rate (0%) in a study that only included patients aged less than 16 years. No papers evaluated the health outcomes in patients tested compared with those not tested. Nevertheless, a positive test always a¡ected management.
Blood gases
Abnormal results were shown to be present in 0--22.0% of patients with no changes in management resulting (one study did indicate changes in management but did not specify what constituted a change and was therefore excluded) and post-operative complications in 1.8--5.1%. However, there were too few case series to allow trends of test utility and there was no information on ASA grading. The de¢nitions of an abnormal result were either not given or were inconsistent between di¡erent studies. No papers evaluated the health outcomes in patients tested compared with those not tested. Consequently, the evidence available was insuf-¢cient to determine whether these tests did or did not a¡ect patient outcome.
Plasma glucose
The guidelines expect plasma glucose to have been measured at some time in the past in primary care and that testing two weeks before surgery is inappropriate.
It is surprising that measurement of plasma glucose testing is not recommended for patients over 80 with signi¢cant co-morbidities, a poor anaesthetic rating or having any major surgery. This may be an opportunity missed, given my experience in a lipid clinic where it is not unusual to ¢nd undiagnosed diabetics of all ages who are 'on a waiting list for surgery'.
Since the evidence summarized above was either poor or non-existent, the NICE working group surveyed clinical opinion on preoperative testing by interviewing trainee surgeons and consultant anaesthetists and then submitted their opinions for review by four multidisciplinary focus groups, all of which included a haematologist and a clinical biochemist. Decisions on advice were then based on consensus with a 75% majority required to deem an item conclusive; less than 75% concordance meant the item was considered unclear.
Other guidelines
Guidelines for many clinical situations have been produced by bodies from all over the world. Other UK guideline writing bodies include the Scottish Intercollegiate Network (SIGN), which has not evaluated this area. I searched a variety of guideline repositories, including Cochrane collaboration libraries (http:// www.cochrane.org), the National Guideline Clearing House (http://guideline.gov), the American Association of Family Physicians (http://www.aafp.org), and the Ontario Guidelines Advisory Committee (http:// gacguidelines.ca) among others, but none had compiled their own guidelines and all simply referred me back to the NICE guideline. There are also numerous site-speci¢c guidelines available on the Internet (e.g. guidelines from the University Hospital of Cleveland Department of Anaethesiology [http://www. uhcanesthesia.com/PAT/Surgeons/lab-testing (accessed 23/06/05)]), but these may not be appropriate to UK health-care practices. For example, the Cleveland guidelines include advice on diagnoses that can be used to justify tests to ensure Medicare reimbursement. It therefore appears that NICE may be the ¢rst to have attempted to evaluate this area and as such they should be applauded. However, this really demonstrates that further work needs to be carried out.
Problems with implementation of the guidelines Categorization of patients
The guidance on testing relates to groups of patients categorized by age, surgical grade, anaesthetic grade, and co-morbidity. Age and co-morbidity are relatively easy to de¢ne, but there are problems with the other two variables. Little is known about the reproducibility of ASA grades for anaesthetic risk and a Medline search revealed only two papers dealing with this issue. One paper demonstrated that data collected from patients using questionnaires are unreliable 2 and the other showed that, in a survey of 113 anaesthetists in Northern England, it was not possible to agree on ASA scores in 10 hypothetical patients. In only one case was it possible for the grades to be restricted to two of the ¢ve possibilities. 3 For grading surgical risk, the problem is even greater. The NICE working group could not identify any widely accepted scale to assess the 'stressfulness' of surgical procedures, and therefore a simple 4-point scale was devised, with grade 1 being de¢ned as minor (excision of skin lesion or drainage of breast abscess), grade 2 as intermediate (primary repair of inguinal hernia, excision of varicose veins, tonsillectomy, or knee arthroscopy), grade 3 as major (total abdominal hysterectomy, endoscopic prostate resection, thyroidectomy or lumbar discectomy) and grade 4 as major þ (total joint replacement, lung operation, colonic resection, radical neck dissection, cardiac or neuro-surgery). Clearly, this leaves many grey areas: where, for example, would one place a vaginal hysterectomy on the scale? Would a nurse in a pre-admission clinic be able to grade the wide variety of operations and is there any operator dependency? This uncertainty, together with concerns about litigation in cases where the patient developed complications post-operatively, could lead to considerable potential for over-grading and consequent over-investigation. Since the surgical scale is empirically designed speci¢cally for the guidelines there is no data on reproducibility.
Complexity of the guidelines
Guidance on the need for each type of test is provided in separate colour-coded matrices relating to speci¢c patient categories. Thus, there are speci¢c tables for patients with no co-morbidities, co-morbidity from cardiovascular disease, co-morbidity from renal disease and co-morbidity from respiratory disease. Advice is also given for up to nine age bands and four ASA grades plus cardiac surgery and neurosurgery, resulting in 62 separate tables of advice. This is translated into two complex £ow charts allowing selection of tests from 36 di¡erent tables for each of anaesthetic or surgical grade. Finally, there are two extra tables that apply to all women (for pregnancy testing) and all ethnic minorities likely to carry the sickle cell gene (74 tables in total).
Given the volume of advice, it would be inconceivable that anyone would be able to remember all of the guidance. Furthermore, since patient category determines whether it is necessary to collect samples, it would be of little use to supply the required pieces of data to the laboratory and expect the booking in sta¡ to decide whether or not to order speci¢c tests. The only way in which the guidance could be consistently applied therefore would be to use an information technology (IT) solution. The Queen's Hospital in Burton-on-Trent has a ward order entry system that allows order sets to be compiled but does not, to my knowledge, allow multi-branched decision trees, so each individual combination in the guidance would need to be manually programmed --a very large task which would either provide so many menu options that it would be di⁄cult for anyone to choose the correct option or be too complex to program and test without considerable IT support. This would seriously restrict the e¡ectiveness of any attempt to introduce the guidance as a hospital-wide or NHS-wide policy.
Timelines of preoperative testing
No evidence was found by the guideline working group to enable de¢nition of time limits for the utility of tests. Neither could any consensus on this issue be reached. It therefore remains a matter of conjecture how long before elective operation is it reasonable to carry out pre-assessment.
Cost
Rationalization of preoperative testing is clearly a sensible mechanism to reduce inequalities and unnecessary testing (if this is being carried out). However, it is possible that current practice is less rigorous than the structure proposed in the NICE guidance. Implementation of the guidelines could conceivably result in a signi¢cant increase in demand for laboratory testing, possibly without improving outcomes.
It would therefore be unwise to implement the guidelines without ¢rst auditing current practice to determine whether there are cost implications.
Discussion
The NICE guidance on use of routine preoperative testing for elective surgery is a logical attempt to rationalize medical practice, but is based on clinician consensus rather than any de¢nite evidence base. It is therefore eminence-based rather than evidence-based medicine. There may be potential bene¢ts from using the guidelines, such as avoiding litigation, but there are also possible pitfalls, such as assuming that diabetes has been previously excluded when it may not have been considered at all.
We have previously shown that a complex grading system leads to more diversity of opinion than a simple 5-point grading scale. 4 The current NICE system e¡ectively creates many hundreds of grades by multiplying the outcomes of two highly imprecise grades and the result may be very imprecise indeed. This does not, however, mean the advice is of no value. Indeed, the discussion in the NICE document recognizes the problems and suggests that the guidelines may simply represent current practice, which is already known to be extremely diverse. The utility of the guidance is therefore not identi¢able at present, and will be determined by whether it is practical to apply, and whether it will result in a change in practice that is sustainable and bene¢ts patients.
It may be that instead of being the basis for immediate changes to hospital practice, the NICE guidance should be the template for a Government-sponsored Health Technology Assessment project. This could evaluate whether the template, or another more or less test-intensive version, a¡ects intra-operative and post-operative morbidity and mortality. This may allow development of a suitable model that could inform not just the UK but the whole world on the best preoperative assessment scheme for patients undergoing elective surgery.
What kind of evidence do we need?
It is clear that the evidence available to NICE, on which the guidelines are based, is grossly insu⁄cient for the purpose. If we accept that we need guidance on this issue, and the drive towards evidence-based healthcare would suggest that we do, then we have to suggest mechanisms by which appropriate evidence can be collected. The complexity of the ¢eld means it would be di⁄cult to assess all areas in a single study, particularly as the di¡erent grades of surgery and anaesthetic risk and issues of case-mix in di¡erent centres would further complicate the issue. I would therefore suggest that it would be appropriate for a full Health Technology Assessment project to look into this issue. This should be a primary (i.e. trial-led) rather than secondary (i.e. literature-based) project, since we already know the literature does not exist. Due to the ethical problems of screening versus not screening for preoperative conditions, it would be necessary to compare 'usual practice' (possibly formalized to ensure consistency) against the NICE guidance. It would also be necessary to evaluate (and possibly develop) an e⁄cient reproducible surgical and anaesthetic grading scheme (possibly to replace the ASA grades which have been shown to be inconsistent).
Conclusion
In conclusion, NICE has attempted to create guidelines to rationalize use of preoperative testing. I searched a variety of guideline repositories, including the Scottish Intercollegiate Network (SIGN), Cochrane collaboration libraries, the National Guideline Clearing House, the American Association of Family Physicians and the Ontario Guidelines Advisory Committee, but none had compiled their own guidelines; they simply referred back to the NICE guidelines. Unfortunately the evidence available to NICE on which to base such guidelines is so sparse and inconsistent that it is impossible to draw any meaningful conclusions from it. It is therefore far too early to consider implementation of the NICE guideline in routine clinical practice. It would, however, be appropriate to consider it as part of a randomized clinical trial comparing the guideline with usual practice to evaluate whether the NICE guideline improves outcomes or, failing improvement in outcome, makes signi¢cant cost-e⁄ciency savings with minimum clinical penalty.
